西班牙ITP患者从其他TPO-RA转换至阿伐曲泊帕的真实世界研究
西班牙ITP研究组纳入208例因无效、便利性或不良事件从艾曲泊帕或罗米司亭转换至阿伐曲泊帕的ITP患者,中位随访63.9周。6.7%因不良事件停药,血栓栓塞率3.8%,无新安全性问题。
要点
- 转换后6.7%因不良事件停药,血栓栓塞率3.8%,无新安全性问题。
核心结论
- 在大型真实世界队列中,从艾曲泊帕或罗米司亭转换至阿伐曲泊帕可安全诱导持久的血小板计数恢复。
研究设计与样本
- 西班牙ITP研究组(GEPTI)开展的真实世界队列研究,纳入208例因无效、便利性或不良事件从艾曲泊帕或罗米司亭转换至阿伐曲泊帕的ITP患者。
- 患者中位随访63.9周(四分位距31.1-100.4周)。
主要发现
- 转换原因:无效115例(55.3%)、便利性66例(31.7%)、治疗中出现不良事件(TEAEs)27例(13.0%)。
- 应答者在56.4周(四分位距24.6-90.2周)后81.2%维持应答。
临床怎么用
- 对其他TPO-RA无效或不耐受的ITP患者,可考虑转换至阿伐曲泊帕以恢复血小板计数。
- 因便利性或不良事件转换者,阿伐曲泊帕可在较低维持剂量下维持长期应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avatrombopag is a thrombopoietin receptor agonist (TPO-RA) suitable for patient-centred care. Avatrombopag achieved lasting platelet count (PC) increases in small series of immune thrombocytopenia (ITP) patients in whom other TPO-RAs had failed. We recruited 208 patients with ITP who switched from eltrombopag or romiplostim to avatrombopag due to ineffectiveness (115 [55.3%]), convenience (66 [31.7%]) or treatment-emergent adverse events (TEAEs) (27 [13.0%]). Patients were followed up for 63.9 (31.1-100.4) weeks (median [interquartile range]). Ninety-two per cent of switchers due to ineffectiveness who had baseline PC <50 × 109/L responded to avatrombopag (PC ≥50 × 109/L with doubling of baseline values). Response was maintained in 81.2% of patients after 56.4 (24.6-90.2) weeks. Ninety-two per cent of switchers due to convenience or TEAEs maintained a long-term response. Fifty-one per cent of switchers due to TPO-RA failure who used concomitant medications discontinued these while on avatrombopag. In switchers due to convenience or TEAEs, the maintenance dose decreased from 140 (140-140) to 80 (60-140) mg/week. Fourteen patients (6.7%) discontinued avatrombopag due to TEAEs. The thromboembolism rate was 3.8%. No new safety concerns arose. In this large real-world cohort, switching from eltrombopag or romiplostim to avatrombopag safely induced durable PC recovery.
引用
- Pascual-Izquierdo C, Bastida JM, Valcárcel D, et al. Switching patients with immune thrombocytopenia (ITP) to avatrombopag from other thrombopoietin receptor agonists: The real-world experience of the Spanish ITP Group (GEPTI). Br J Haematol. 2026. PMID: 42216511. doi:10.1111/bjh.70595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。